Cuban-China Joint Venture Plans Clinical Trials and Cancer Drug Production in China

Yanet Borrego, deputy general director and representative of BPL's vice-presidency in Cuba, said that the joint venture Biotech Pharmaceuticals Limited (BPL) is preparing clinical trials in China for the monoclonal antibody Itolizumab, which is registered in Cuba and used to treat autoimmune illnesses.

 According to a report in Prensa Latina, she continued, these studies would concentrate on graft-versus-host disease and dermatomyositis.

The BPL representative noted that the joint venture is anticipated to be prepared to begin production and clinical trials of this medication in China between 2025 and 2026. They are currently in the process of transferring the technology associated with the production process of Cimavax, the Cuban vaccine against lung cancer.She said that nimotuzumab, a medication for head and neck cancer, was just authorised in the Asian Giant.

Elizabeth Arias Valdés, general manager of Cimab, S.A., the business that owns BPL, told Granma that this product is the firm's top seller, selling over 100 million copies a year, and is regarded as one of the key offerings of Cuban biotechnology.

According to Borrego, the firm is also developing nine cutting-edge items in partnership with the Cuban side. These products are now in the research and development stage and should be available for purchase in ten years or less.